NCT07168421View on ClinicalTrials.gov

LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

March 1, 2028

Conditions
Perioperative Myocardial InjuryAutonomic DysfunctionCardiovascular (CV) RiskMajor SurgeryBeta BlockerMyocardial Injury After Non-cardiac Surgery
Interventions
DRUG

Landiolol

The main dose range is 1-40 mcg/kg/min, titrated to the effect on heart rate aiming for a heart rate of below 90 beats per minute throughout. This dose can be decreased to 0 if heart rate stays below target.

Trial Locations (1)

3010

Bern University Hospital, Freiburgstrasse, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER